ELSALYS BIOTECH | Managers | Title | Age | Since |
|---|---|---|---|
Martine Brandt
FOU | Founder | - | 12-12-31 |
Thierry Menguy
FOU | Founder | - | 12-12-31 |
Vanessa Duong
FOU | Founder | - | 12-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | - | 12-12-31 | |
Eric Quéméneur
CTO | Chief Tech/Sci/R&D Officer | 60 | - |
Mizrahi Jacques
CTO | Chief Tech/Sci/R&D Officer | 70 | 13-12-31 |
ElsaLys Biotech specializes in the design and development of new-generation antibodies intended to modulate the immune systems of patients suffering from cancer or rare blood diseases.
The company has a portfolio of 5 programs in the development phase, including LEUKOTAC® (Inolimomab), an immunotherapy antibody demonstrating a clinical benefit in Phase 3 of a rare disease with a very poor prognosis: acute steroid resistant reaction of the graft against the host.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +24.60% | 654B | |
| +24.08% | 552B | |
| -5.63% | 356B | |
| +15.37% | 319B | |
| +7.38% | 295B | |
| +3.26% | 211B | |
| +0.78% | 206B | |
| -9.69% | 147B | |
| -6.63% | 144B |
